valu usd unless otherwis note
troubl
view report in-lin provid disappoint initi
guidanc challeng pharmedium continu compound
maintain sector perform rate share
result ok guid less report in-lin result today
provid initi guidanc street troubl
pharmedium challeng core busi continu weigh
outlook report ep ahead
street segment miss op target vs
model deliv beat lower interest expens
tax rate provid initi guidanc rang
consensu hinder pharmedium share fell
outlook
pharmedium continu face challeng call manag
note pharmedium memphi facil remain close
remain close fiscal year itd low single-digit
headwind op given strong close decemb
manag also said product three facil
compromis compani implement enhanc precaut
make sure remain oper suspect pharmedium
turnaround could take time given doj consum protect
branch also involv process mean result like
come toward low end guidanc
trim estim lower estim
reflect continu challeng pharmedium pharma distribut
segment revenu estim reflect lower growth rate
push restart pharmedium memphi facil lower
pharma revenu forecast ad expens across four pharmedium
facil modest increas expens pharma busi
result lower growth rate adjust oper incom
segment compar prior forecast growth
segment oper profit forecast larg unchang
better oper profit growth off-set lower result
ep estim low end guidanc
maintain sector perform trim pt maintain sector perform
rate share trim price target reflect
revis ep estim
price prior trade day market close estimate unless otherwis note
believ share like multipl rang bound
investor get visibl gener drug price
bottom oper earn growth resum
pressur last
month multipl issu relat drug price
weigh result expect backdrop
improv next month howev believ
best-posit wholesal
meet earn target given conserv guidanc
relationship walgreen though note
rel strength seem reflect current share
estim gener profit
core us drug distribut busi sale gener
drug past two year seen
price gener drug deflat high-single-digit mid-
teen percentag rate profit dollar contribut
fall slightli lower rate gener deflat continu
high-single-digit pace higher believ
volum growth abl
grow earn segment though may best
posit creat spread price fall
upsid risk sector perform rate share
includ stabil drug price environ
could caus earn estim stabil like drive
multipl expans close market multipl
downsid risk sector perform rate includ
acceler drug price deterior gener
market potenti client loss wholesal
sell-sid price compress larger pharmaci
custom gpo
bloomberg capit market estim upside/downside/target
price target share equal
ep estim use multipl reflect
slight discount averag forward trade
multipl share due uncertainti surround
upsid scenario share base
ep estim higher base case price-to-earnings
multipl appli ep scenario upsid scenario
ep better ep growth could
driven success partnership walgreen increas
volum across brand gener drug success capit
deploy level gener price deflat
forward multipl repres high end
normal trade rang drug wholes space
multipl like get neg
downsid scenario share base
ep estim base case price-to-earnings multipl
appli ep scenario downsid scenario
ep lower-than-expect ep could
driven worse-than-expect price environ
lower-than-expect brand gener volum lack
avail opportun forward multipl
like get posit share
result varianc tabl act commentspharmaceut linedistribut adj beat vs estimateoth adj adj adj gross distribut consol intagibles- oper adj adj adj oper adj adj total adj op loss- expens tax tax rate help epsnet per street number share marginoper marginamerisourcebergenbp changebp chang healthcar technolog distribut
price target share support sector perform rate equal
ep estim use multipl reflect slight discount
averag forward trade multipl share due uncertainti surround
risk rate price target
forese upsid downsid risk sector perform rate share
upsid risk includ stabil drug price environ could caus earn
estim stabil like drive multipl expans close market multipl
downsid risk includ acceler drug price deterior gener market
potenti client loss wholesal sell-sid price compress
larger pharmaci custom gpo
pharmaceut distribut consult compani oper
distribut segment
distribut segment includ amerisourcebergen drug corpor abdc
compani amerisourcebergen consult servic abc world courier mwi
veterinari suppli busi partnership walgreen boot
allianc global drug sourc distribut product locat
good sold
segment revenu
segment revenu
amort intang
revenu
segment revenu
segment revenu
incom discontinu oper net tax
net loss attribut non-controlling interest
net incom attribut
earn per share continu oper
weight average number share
